Sanofi American Depositary Shares (Each representing one-half of one ordinary share) (SNY) Financial Statements
Historical financial data — 5 statements covering FY2021–FY2025
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, acc...
Sanofi American Depositary Shares (Each representing one-half of one ordinary share)'s revenue increased 5.5% year over year, from $44.29B to $46.72B.
Net income increased 40.5% over the same period, from $5.56B to $7.81B.
Over the 4-year period from FY2021 to FY2025, revenue grew by 19% in total.
Total debt increased by 13.5% to $20.33B.
The debt-to-equity ratio stands at 0.28, indicating a conservative leverage profile.
Sanofi American Depositary Shares (Each representing one-half of one ordinary share) maintains a healthy net profit margin of 16.7%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2021 | $39.17B | $6.22B | $26.92B | $8.13B | N/A | $120.24B | $22.41B | $69.03B |
| FY2022 | $40.56B+3.5% | $8.37B | $28.68B | $10.16B | N/A | $126.72B | $21.21B | $75.15B |
| FY2023 | $41.62B+2.6% | $5.40B | $28.99B | $6.96B | N/A | $126.46B | $18.42B | $74.35B |
| FY2024 | $44.29B+6.4% | $5.56B | $31.08B | $7.25B | N/A | $132.80B | $17.91B | $77.86B |
| FY2025 | $46.72B+5.5% | $7.81B | $33.67B | $6.34B | N/A | $126.81B | $20.33B | $71.71B |